Literature DB >> 11123859

Oligodendroglioma.

.   

Abstract

Before treatment can be initiated, an accurate histopathologic diagnosis must be made. There is still some controversy regarding histologic criteria for the diagnosis of oligodendroglioma and which grading system is best. Molecular diagnosis is becoming an important adjunct to traditional histopathologic diagnosis. For low-grade oligodendrogliomas, maximal surgical resection should be attempted if technically feasible. Radiation therapy or chemotherapy should be deferred unless the patient has significant neurologic symptoms or growth of tumor. Aggressive or anaplastic tumors should also be treated with maximal surgical resection. Increasingly, chemotherapy is replacing radiation therapy as the initial postoperative treatment, with radiation therapy being either delayed until after completion of chemotherapy or, in select patients, deferred until recurrence.

Entities:  

Year:  2001        PMID: 11123859     DOI: 10.1007/s11940-001-0024-7

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  17 in total

1.  Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

Authors:  G Cairncross; L Swinnen; R Bayer; S Rosenfeld; D Salzman; N Paleologos; L Kaminer; P Forsyth; D Stewart; K Peterson; W Hu; D Macdonald; D Ramsay; A Smith
Journal:  Neuro Oncol       Date:  2000-04       Impact factor: 12.300

2.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

3.  The role of postoperative irradiation in the treatment of oligodendroglioma.

Authors:  D E Gannett; W M Wisbeck; D L Silbergeld; M S Berger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-10-15       Impact factor: 7.038

4.  Salvage chemotherapy for oligodendroglioma.

Authors:  K Peterson; N Paleologos; P Forsyth; D R Macdonald; J G Cairncross
Journal:  J Neurosurg       Date:  1996-10       Impact factor: 5.115

5.  The treatment of anaplastic oligodendrogliomas and mixed gliomas.

Authors:  A P Kyritsis; W K Yung; J Bruner; M J Gleason; V A Levin
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

6.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

7.  Low-grade oligodendroglioma responds to chemotherapy.

Authors:  W P Mason; G S Krol; L M DeAngelis
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

8.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

9.  Cerebral oligodendroglioma: prognostic factors and life history.

Authors:  P Celli; I Nofrone; L Palma; G Cantore; A Fortuna
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

10.  Successful chemotherapy for recurrent malignant oligodendroglioma.

Authors:  J G Cairncross; D R Macdonald
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

View more
  3 in total

1.  Unusual intracranial spread of anaplastic oligodendroglioma.

Authors:  Ali Akhavan; Fariba Binesh; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2012-08-13

2.  Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

3.  Extracranial metastasis of anaplastic oligoastrocytoma.

Authors:  Zhuang Kang; Shoubo Yang; Hongmei Zhang; Quan Zhou; Jianxin Chen; Yan Li; Xun Kang; Shan Li; Wenbin Li
Journal:  Cancer Biol Med       Date:  2018-08       Impact factor: 4.248

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.